Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer. Zhou Y, Yang X, Tian T, Yang B, et al. Front Immunol 2026;17:1896444.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhou Y, Yang X, Tian T, Yang B, et al. Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer. Front Immunol 2026;17:1896444.
PMID: 42582256